Gilead Exercises Option for Kymera's KT-200 CDK2 Degrader, Triggering $45M Milestone Payment
核心洞察
Gilead Sciences has exercised its option to exclusively license KT-200 (搜索), Kymera Therapeutics (搜索)' first-in-class oral CDK2 (搜索) molecular glue degrader, triggering a $45 million milestone payment.
KT-200 (搜索) demonstrated low-nanomolar CDK2 (搜索) degradation and robust activity in preclinical studies, with potential applications in CCNE1 (搜索)-driven cancers including advanced breast cancer.
The collaboration could yield up to $750 million in total payments for Kymera, with Gilead planning to advance KT-200 (搜索) into IND-enabling studies targeting a 2027 IND filing.
Gilead Sciences has exercised its option to exclusively license KT-200 (搜索), a first-in-class oral CDK2 (搜索) molecular glue degrader developed by Kymera Therapeutics (搜索), under their strategic collaboration agreement. The option exercise triggers a $45 million milestone payment to Kymera and represents a significant advancement in targeted protein degradation therapy for cancer treatment.
Novel Therapeutic Approach for Cancer Treatment
KT-200 (搜索) represents a breakthrough in cancer therapeutics as a CDK2 (搜索)-directed molecular glue degrader designed to selectively eliminate the CDK2 protein rather than merely inhibiting its activity. CDK2 acts as a cyclin E binding partner and drives disease progression in CCNE1 (搜索) amplified and overexpressed cancers. This targeted approach has the potential to deliver safer and more effective oral treatments for CDK2-driven cancers, particularly in advanced breast cancer where treatment options remain limited.
Traditional CDK2 (搜索) inhibitors often lack specificity and interfere with closely related proteins, leading to undesired side effects. The molecular glue degrader approach offers the potential for more precise, safe, and effective oral treatments for cancers that rely on CDK2 activity.
Strong Preclinical Performance
In preclinical testing, KT-200 (搜索) demonstrated compelling therapeutic potential with low-nanomolar CDK2 (搜索) degradation and robust activity in CCNE1 (搜索) amplified, overexpressed cell lines and in vivo tumor models. The compound also showed brain penetrant potential and maintained a favorable safety profile, positioning it as a promising candidate for clinical development.
"KT-200 (搜索) is expected to be the first molecular glue discovered by Kymera to enter the clinic, reflecting the company's ability to apply our discovery capabilities to some of the most challenging disease-causing targets," said Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics (搜索). "KT-200's compelling preclinical profile demonstrates its potential to transform the therapeutic landscape for patients with cancers that remain difficult to treat."
Development Timeline and Financial Terms
Gilead plans to advance KT-200 (搜索) into investigational new drug (IND)-enabling studies with the goal of supporting an IND filing in 2027. Under the collaboration agreement established in June 2025, Kymera is eligible to receive up to $750 million in total payments contingent on achieving specified development, regulatory, and commercial milestones.
To date, Kymera has realized $85 million in upfront and option exercise payments from the partnership. The company also stands to benefit from tiered royalties on net product sales ranging from high single digits to mid-teens. While Kymera leads all research activities for the CDK2 (搜索) program, Gilead retains global rights to develop, manufacture, and commercialize any products arising from the collaboration.
Market Impact and Strategic Significance
The option exercise underscores the growing interest in targeted protein degradation as a therapeutic modality for addressing previously undruggable targets in oncology. Kymera's molecular glue degrader platform represents an innovative approach to drug discovery, particularly for challenging disease-causing targets that have been difficult to address with conventional therapeutics.
Year to date, Kymera's shares have rallied 12.3% compared with the biotech industry's 2.1% growth, reflecting investor confidence in the company's targeted protein degradation platform and strategic partnerships.